MAZE THERAPEUTICS INC (MAZE) Stock Overview
NASDAQ:MAZE - US5787841007 - Common Stock
MAZE Key Statistics, Chart & Performance
The current stock price of MAZE is 13.14 USD. In the past month the price decreased by -19.8%.
MAZE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 43.26 | 661.29B | ||
| JNJ | JOHNSON & JOHNSON | 17.88 | 430.49B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 14.65 | 252.56B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18 | 247.73B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.21 | 243.44B | ||
| MRK | MERCK & CO. INC. | 11.1 | 213.56B | ||
| PFE | PFIZER INC | 7.46 | 143.82B | ||
| SNY | SANOFI-ADR | 11.43 | 122.94B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.02 | 96.19B | ||
| GSK | GSK PLC-SPON ADR | 8.84 | 80.03B | ||
| ZTS | ZOETIS INC | 24.99 | 68.89B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 52.21 | 47.82B |
Related stock screener links
About MAZE
Company Profile
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. The company is headquartered in South San Francisco, California and currently employs 125 full-time employees. The company went IPO on 2025-01-31. The firm is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
Company Info
MAZE THERAPEUTICS INC
171 Oyster Point Boulevard, Suite 300
South San Francisco CALIFORNIA US
Employees: 125
Phone: 16508505070
MAZE THERAPEUTICS INC / MAZE FAQ
What is the stock price of MAZE THERAPEUTICS INC today?
The current stock price of MAZE is 13.14 USD. The price decreased by -2.59% in the last trading session.
What is the ticker symbol for MAZE THERAPEUTICS INC stock?
The exchange symbol of MAZE THERAPEUTICS INC is MAZE and it is listed on the Nasdaq exchange.
On which exchange is MAZE stock listed?
MAZE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MAZE THERAPEUTICS INC stock?
12 analysts have analysed MAZE and the average price target is 24.99 USD. This implies a price increase of 90.18% is expected in the next year compared to the current price of 13.14. Check the MAZE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MAZE THERAPEUTICS INC worth?
MAZE THERAPEUTICS INC (MAZE) has a market capitalization of 576.19M USD. This makes MAZE a Small Cap stock.
How many employees does MAZE THERAPEUTICS INC have?
MAZE THERAPEUTICS INC (MAZE) currently has 125 employees.
What are the support and resistance levels for MAZE THERAPEUTICS INC (MAZE) stock?
MAZE THERAPEUTICS INC (MAZE) has a support level at 13.47 and a resistance level at 13.5. Check the full technical report for a detailed analysis of MAZE support and resistance levels.
Is MAZE THERAPEUTICS INC (MAZE) expected to grow?
The Revenue of MAZE THERAPEUTICS INC (MAZE) is expected to decline by -100% in the next year. Check the estimates tab for more information on the MAZE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MAZE THERAPEUTICS INC (MAZE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MAZE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MAZE, evaluating the profitability, health, valuation and growth aspects
- MAZE THERAPEUTICS INC (MAZE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MAZE THERAPEUTICS INC (MAZE) Sales and EPS estimates to see what analysts future expectations are.
- MAZE THERAPEUTICS INC (MAZE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MAZE THERAPEUTICS INC (MAZE) Insider and Institutional Ownership to learn about the owners and their transactions.
- MAZE THERAPEUTICS INC (MAZE) Stock Chart to make your own analysis
- MAZE THERAPEUTICS INC (MAZE) Latest news and press-releases to stay up to date.
Does MAZE THERAPEUTICS INC (MAZE) stock pay dividends?
MAZE does not pay a dividend.
What is the Price/Earnings (PE) ratio of MAZE THERAPEUTICS INC (MAZE)?
The PE ratio for MAZE THERAPEUTICS INC (MAZE) is 164.25. This is based on the reported non-GAAP earnings per share of 0.08 and the current share price of 13.14 USD. Check the full fundamental report for a full analysis of the valuation metrics for MAZE.
What is the Short Interest ratio of MAZE THERAPEUTICS INC (MAZE) stock?
The outstanding short interest for MAZE THERAPEUTICS INC (MAZE) is 4.33% of its float. Check the ownership tab for more information on the MAZE short interest.
MAZE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to MAZE.
MAZE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to MAZE. While MAZE has a great health rating, its profitability is only average at the moment.
MAZE Financial Highlights
Over the last trailing twelve months MAZE reported a non-GAAP Earnings per Share(EPS) of 0.08. The EPS increased by 103.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2.03% | ||
| ROA | 1.42% | ||
| ROE | 1.73% | ||
| Debt/Equity | 0 |
MAZE Forecast & Estimates
12 analysts have analysed MAZE and the average price target is 24.99 USD. This implies a price increase of 90.18% is expected in the next year compared to the current price of 13.14.
For the next year, analysts expect an EPS growth of 84.51% and a revenue growth -100% for MAZE